Vedroprevir

An investigational antiviral drug

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (1R,18R,20R,24S,27S)-N-[(1R,2R)-2-[[4-(difluoromethoxy)phenyl]methyl]cyclopropyl]-1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28-octacosahydro-20,27-dihydroxy-24-isopropyl-1,18-dimethyl-3,6,9,12,15,22-hexaoxo-2,5,8,11,14,17,21-heptaazacyclooctacosane-4-carboxamide | image = | width = | alt = | tradename = | Drugs.com = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 12345678 | DrugBank = DB12345 | ChemSpiderID = 123456 | UNII = 123456789A | KEGG = D12345 | ChEBI = 12345 | ChEMBL = 1234567 | C=40 | H=50 | F=2 | N=6 | O=8 | smiles = | InChI = | InChIKey = }}

Vedroprevir is an investigational antiviral drug that has been studied for its potential use in the treatment of hepatitis C virus (HCV) infections. It belongs to a class of drugs known as protease inhibitors, which work by inhibiting the action of the NS3/4A protease enzyme, a critical component in the viral replication process of HCV.

Mechanism of Action

Vedroprevir targets the NS3/4A serine protease, an enzyme essential for the cleavage of the HCV polyprotein into functional viral proteins. By inhibiting this enzyme, vedroprevir disrupts the viral life cycle, thereby reducing viral replication and aiding in the clearance of the virus from the host.

Clinical Development

Vedroprevir has undergone various phases of clinical trials to evaluate its safety, efficacy, and pharmacokinetics. Early studies have shown promising results in reducing viral load in patients with chronic HCV infection. However, as with many investigational drugs, further studies are required to fully establish its clinical utility and to compare its effectiveness with existing therapies.

Side Effects

As an investigational drug, the side effect profile of vedroprevir is still being characterized. Common side effects observed in clinical trials include fatigue, headache, and nausea. More serious adverse effects are being monitored as part of ongoing research.

Potential for Combination Therapy

Given the complex nature of HCV and the potential for resistance development, vedroprevir is often studied in combination with other antiviral agents. Combination therapy aims to enhance antiviral efficacy and reduce the likelihood of resistance.

Regulatory Status

As of the latest updates, vedroprevir has not yet received approval from major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains an investigational compound under clinical evaluation.

Also see

• Hepatitis C virus
• Protease inhibitor (pharmacology)
• Antiviral drug
• NS3/4A protease

Drugs for HIV Infection, in the Subclass Antiretroviral Agents

• Fusion Inhibitors (HIV)
  • Enfuvirtide, Maraviroc

• Integrase Inhibitors (HIV)
  • Dolutegravir, Elvitegravir, Raltegravir

• Monoclonal Antibodies
  • Ibalizumab

• Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
  • Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine

• Nucleoside Analogues (HIV)
  • Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine

• Protease Inhibitors (HIV)
  • Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir

Drugs for Hepatitis B

• Alpha Interferon, Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine, Tenofovir

Drugs for Hepatitis C

• Interferon Based Therapies
  • Alpha Interferon and Peginterferon, Ribavirin

HCV NS5A Inhibitors

• Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir, Velpatasvir

HCV NS5B Inhibitors (Polymerase inhibitors)

• Dasabuvir, Sofosbuvir

HCV Protease Inhibitors

• Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir

Combination Therapies

• Epclusa, Harvoni, Mavyret, Technive, Viekira Pak, Vosevi, Zepatier

Drugs for Herpes Virus

• infections (HSV), CMV, others

Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir

Drugs for Influenza

• Amantadine, Oseltamivir, Peramivir, Rimantadine, Zanamivir